Podravka (PODR) investor relations material

Executive summary

• Operating revenues increased by 2.0% year-over-year to EUR 256.9m, with growth in Food and Pharmaceuticals segments offsetting a slight decline in Agri revenues.

• Normalised net profit after minorities rose by 4.7% to EUR 21.0m, driven by process improvements and cost optimisation.

• Reported results were significantly impacted by one-off items, including EUR 16.7m in tax incentives for Pharmaceuticals and the absence of a EUR 55.04m gain from the prior year’s Agri acquisition.

Financial highlights

• Sales revenues grew 1.8% year-over-year to EUR 249.3m; other operating revenues up 8.4%.

• Gross profit decreased by 1.1% to EUR 84.3m; gross margin declined to 32.8%.

• Normalised EBITDA increased by 0.8% to EUR 45.2m; normalised EBIT stable at EUR 29.9m.

• Cost of goods sold increased by 3.5%, general and administrative expenses fell by 1.8%, and selling/distribution costs dropped by 3.3%.

• Net cash from operating activities was EUR 22.7m, up 22.4% year-over-year.

Outlook and guidance

• Process improvements and cost discipline are expected to continue supporting profitability.

• Expansion in principal's distribution in the US and growth in key European markets are expected to drive further revenue growth.

• Capital expenditures for 2026 are expected to reach approximately EUR 78m, focusing on agricultural machinery, irrigation, and production line upgrades.